For the first time in decades, a new class of painkiller has been approved by the US Food and Drug Administration (FDA).

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

Biotechnology company Vertex Pharmaceuticals (VRTX) reported mixed results for the fourth quarter of 2024. While revenue surpassed analyst ...

Vertex Pharmaceuticals Inc. ( ($VRTX) ) has released its Q4 earnings. Here is a breakdown of the information Vertex Pharmaceuticals Inc. presented ...

Vertex provided 2025 revenue guidance of $11.75 billion to $12 billion, reflecting 8% growth at the midpoint. Growth is expected from U.S. launches of ALYFTREK and JOURNAVX, along with the continued ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.

For the full year, Vertex guided for revenue between $11.75 billion and $12 billion, which includes the U.S. launch of cystic fibrosis treatment for patients aged six and older Alyftrek and early ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 43 tables and 86 figures, this 160-page report ?Europe Biopharmaceuticals Market 2023-2033 by Product Type, Testing Service ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 78 tables and 119 figures, this 215-page report ?Global Biopharmaceuticals Market 2023-2033 by Product Type, Testing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

GE HealthCare today announced a $138 million investment to expand its Carrigtohill, Cork contrast media fill and finish manufacturing site in Ireland. A new state-of-the-art facility on the grounds of ...